Flu Myths: Dispelling the Myths Associated With Live Attenuated Influenza Vaccine

World Health Organization Reid, 1999, Origin and evolution of the 1918 “Spanish” influenza virus hemagglutinin gene, Proc Natl Acad Sci U S A, 96, 1651, 10.1073/pnas.96.4.1651 Thompson, 2003, Mortality associated with influenza and respiratory syncytial virus in the United States, JAMA, 289, 179, 10.1001/jama.289.2.179 CDC Centers for Disease Control and Prevention Nichol, 1996, Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial, Arch Intern Med, 156, 1546, 10.1001/archinte.1996.00440130090009 Margolis, 1990, Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial [published correction appears in JAMA. 1991;265(21):2810], JAMA, 264, 1139, 10.1001/jama.1990.03450090075029 Govaert, 1993, Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial, BMJ, 307, 988, 10.1136/bmj.307.6910.988 Wilde, 1999, Effectiveness of influenza vaccine in health care professionals: a randomized trial, JAMA, 281, 908, 10.1001/jama.281.10.908 Bridges, 2000, Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial, JAMA, 284, 1655, 10.1001/jama.284.13.1655 Demicheli, 2000, Prevention and early treatment of influenza in healthy adults, Vaccine, 18, 957, 10.1016/S0264-410X(99)00332-1 Zangwill, 2004, Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination, Pediatr Infect Dis J, 23, 189, 10.1097/01.inf.0000116292.46143.d6 Gross, 1995, The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature, Ann Intern Med, 123, 518, 10.7326/0003-4819-123-7-199510010-00008 Centers for Disease Control and Prevention (CDC), 1998, Influenza and pneumococcal vaccination levels among adults aged greater than or equal to 65 years—United States, 1997, MMWR Morb Mortal Wkly Rep, 47, 797 Weingarten, 1989, Barriers to influenza vaccine acceptance: a survey of physicians and nurses, Am J Infect Control, 17, 202, 10.1016/0196-6553(89)90129-6 Harper, 2004, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 53, 1 Poland, 2005, Requiring influenza vaccination for health care workers: seven truths we must accept, Vaccine, 23, 2251, 10.1016/j.vaccine.2005.01.043 Maassab, 1969, Biologic and immunologic characteristics of cold-adapted influenza virus, J Immunol, 102, 728 Centers for Disease Control and Prevention Belshe, 1998, The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children, N Engl J Med, 338, 1405, 10.1056/NEJM199805143382002 Nichol, 1999, Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial, JAMA, 282, 137, 10.1001/jama.282.2.137 Edwards, 1994, A randomized controlled trial of cold-adapted and inactivated vaccine for the prevention of influenza A disease, J Infect Dis, 169, 68, 10.1093/infdis/169.1.68 Snyder, 1988, Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines, J Virol, 62, 488, 10.1128/JVI.62.2.488-495.1988 Cha, 2000, Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial, J Clin Microbiol, 38, 839, 10.1128/JCM.38.2.839-845.2000 Buonagurio, 2006, Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting, Virology, 347, 296, 10.1016/j.virol.2005.11.006 Talbot, 2005, Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults, Infect Control Hosp Epidemiol, 26, 494, 10.1086/502574 Murphy, 2002, Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines, Viral Immunol, 15, 295, 10.1089/08828240260066242 Vesikari, 2006, CAIV-T Transmission Study Group. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine, Pediatr Infect Dis J, 25, 590, 10.1097/01.inf.0000220229.51531.47 King, 2000, Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults, J Infect Dis, 181, 725, 10.1086/315246 King, 2001, Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children, Pediatr Infect Dis J, 20, 1124, 10.1097/00006454-200112000-00006 Belshe, 2007, CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children, N Engl J Med, 356, 685, 10.1056/NEJMoa065368 Redding, 2002, Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma, Pediatr Infect Dis J, 21, 44, 10.1097/00006454-200201000-00010 Bergen, 2004, Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents, Pediatr Infect Dis J, 23, 138, 10.1097/01.inf.0000109392.96411.4f Piedra, 2005, Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial, Pediatrics, 116, e397, 10.1542/peds.2004-2258 Fleming, 2006, Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma, Pediatr Infect Dis J, 25, 860, 10.1097/01.inf.0000237797.14283.cf Gorse, 2003, Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study, Vaccine, 21, 2133, 10.1016/S0264-410X(02)00748-X Jackson, 1999, Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions, Vaccine, 17, 1905, 10.1016/S0264-410X(98)00471-X Keitel, 1993, Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults, J Infect Dis, 167, 305, 10.1093/infdis/167.2.305 Edwards, 1991, Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children, J Infect Dis, 163, 740, 10.1093/infdis/163.4.740 Tomoda, 1995, Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response, Vaccine, 13, 185, 10.1016/0264-410X(95)93134-U Treanor, 1998, Evaluation of live, cold-adapted influenza A and B virus vaccines in elderly and high-risk subjects, Vaccine, 16, 1756, 10.1016/S0264-410X(98)00136-4 Powers, 1989, Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines, J Clin Microbiol, 27, 2666, 10.1128/JCM.27.12.2666-2671.1989 Gorse, 1995, Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine, J Infect Dis, 172, 1, 10.1093/infdis/172.1.1 Clements, 1986, Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus, J Clin Microbiol, 24, 157, 10.1128/JCM.24.1.157-160.1986 Gorse, 1996, Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly, J Infect Dis, 173, 285, 10.1093/infdis/173.2.285 Gorse, 1988, Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines, J Clin Microbiol, 26, 911, 10.1128/JCM.26.5.911-918.1988 Johnson, 1986, Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine, J Infect Dis, 154, 121, 10.1093/infdis/154.1.121 Boyce, 1999, Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children, Vaccine, 18, 82, 10.1016/S0264-410X(99)00183-8 Gorse, 1991, Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults, Chest, 100, 977, 10.1378/chest.100.4.977 Clover, 1991, Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses, J Infect Dis, 163, 300, 10.1093/infdis/163.2.300 Belshe, 2000, Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine, J Pediatr, 136, 168, 10.1016/S0022-3476(00)70097-7 Belshe, 2003, Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent, Immunol Allergy Clin North Am, 23, 745, 10.1016/S0889-8561(03)00098-5 Ohmit, 2006, Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines, N Engl J Med, 355, 2513, 10.1056/NEJMoa061850 Belshe, 2000, Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine, J Infect Dis, 181, 1133, 10.1086/315323 Treanor, 1999, Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses, Vaccine, 18, 899, 10.1016/S0264-410X(99)00334-5 Ashkenazi, 2006, Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections, Pediatr Infect Dis J, 25, 870, 10.1097/01.inf.0000237829.66310.85 Treanor, 1992, Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly, Ann Intern Med, 117, 625, 10.7326/0003-4819-117-8-625 US Food and Drug Administration, 2007 Harper, 2005, Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR Recomm Rep, 54, 1 Rosenwald King, 2006, Effectiveness of school-based influenza vaccination, N Engl J Med, 355, 2523, 10.1056/NEJMoa055414